Cardiac preconditioning with sphingosine-1-phosphate requires activation of signal transducer and activator of transcription-3

Cardiovascular Journal of Africa

Volumn 25, Issue 3, 2014, Pages 118-123

  Kelly Laubscher, Roisin F ^a   King, Jonathan C ^a   Hacking, Damian ^a   Somers, Sarin ^a   Hastie, Samantha ^a   Stewart, Tessa ^a   Imamdin, Aqeela ^a   Maarman, Gerald ^a   Pedretti, Sarah ^a   Lecour, Sandrine ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Cardioprotection; Myocardial infarction; Preconditioning; Sphingosine 1 phosphate; STAT 3

Indexed keywords

N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; SPHINGOSINE 1 PHOSPHATE; STAT3 PROTEIN; ALPHA-CYANO-(3,4-DIHYDROXY)-N-BENZYLCINNAMIDE; CARDIOTONIC AGENT; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; STAT3 PROTEIN, MOUSE; STAT3 PROTEIN, RAT; TYRPHOSTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOSOLIC FRACTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART PROTECTION; ISCHEMIA; ISCHEMIC PRECONDITIONING; ISOLATED HEART; MALE; MITOCHONDRION; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION; WESTERN BLOTTING; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HEART INFARCTION PREVENTION; HEART MUSCLE; KNOCKOUT MOUSE; METABOLISM; MOUSE; MYOCARDIAL INFARCTION; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; RATS, WISTAR; SIGNAL TRANSDUCTION; SPHINGOSINE; STAT3 TRANSCRIPTION FACTOR; TYRPHOSTINS;

EID: 84905037715     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2014-016     Document Type: Article

References (37)

1. Hattori R, Maulik N, Otani H, Zhu L, Cordis G, Engelman RM, et al. Role of STAT3 in ischemic preconditioning. J Mol Cell Cardiol 2001; 33(11): 1929-1936. (Pubitemid 33097272)
2. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 2001; 98(16): 9050-9055. (Pubitemid 32743867)
3. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, et al. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 2008; 102(1): 131-135.
4. Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B, et al. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 2005; 112(25): 3911-3918. (Pubitemid 43739489)
5. Lecour S. Multiple protective pathways against reperfusion injury: a SAFE path without Aktion? J Mol Cell Cardiol 2009; 46(5): 607-609.
6. Smith RM, Suleman N, Lacerda L, Opie LH, Akira S, Chien KR, et al. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res 2004; 63(4): 611-616. (Pubitemid 39078674)
7. Gross ER, Hsu AK, Gross GJ. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3 beta. Am J Physiol Heart Circ Physiol 2006; 291(2): H827-34. (Pubitemid 44175091)
8. Rafiee P, Shi Y, Su J, Pritchard KA, Jr, Tweddell JS, Baker JE. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 2005; 100(3): 187-197. (Pubitemid 41348809)
9. Kelly RF, Lamont KT, Somers S, Hacking D, Lacerda L, Thomas P, et al. Ethanolamine is a novel STAT-3 dependent cardioprotective agent. Basic Res.Cardiol 2010; 105(6): 1-8.
10. Lamont KT, Somers S, Lacerda L, Opie LH, Lecour S. Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection. J Pineal Res 201; 50(4): 374-380.
11. Smith CCT, Dixon RA, Wynne AM, Theodorou L, Ong SG, Subrayan S, et al. Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol 2010; 299(4): H1265-H1270.
12. Suleman N, Somers S, Smith R, Opie LH, Lecour SC. Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. Cardiovasc Res 2008; 79(1): 127-133. (Pubitemid 351881934)
13. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J Mol Cell Cardiol 2009; 47(1): 32-40.
14. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002; 34(5): 509-518.
15. Jin ZQ, Goetzl EJ, Karliner JS. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation 2004; 110(14): 1980-1989. (Pubitemid 39331911)
16. Lecour S, Owira P, Opie LH. 2006. Ceramide-induced preconditioning involves reactive oxygen species. Life Sci 2006; 78(15): 1702-1706. (Pubitemid 43276476)
17. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006; 114(13): 1403-1409. (Pubitemid 44454560)
18. Means CK, Xiao CY, Li Z, Zhang T, Omens JH, Ishii I, et al. Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007; 292(6): H2944-2951. (Pubitemid 47084545)
19. Hausenloy, D.J. & Yellon, D.M. 2007. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail.Rev. 12 (3-4), 217-234. (Pubitemid 350176695)
20. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004; 61(3): 448-460. (Pubitemid 38210151)
21. Gurgui M, Broere R, Kalff JC, van Echten-Deckert G. Dual action of sphingosine 1-phosphate in eliciting proinflammatory responses in primary cultured rat intestinal smooth muscle cells. Cell Signal 2010; 22(11): 1727-1733.
22. Loh KC, Leong WI, Carlson ME, Oskouian B, Kumar A, Fyrst H, et al. Sphingosine-1-phosphate enhances satellite cell activation in dystrophic muscles through a S1PR2/STAT3 signaling pathway. PLoS One 2012; 7(5): e37218.
23. Frias MA, James RW, Gerber-Wicht C, Lang U. Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of sphingosine-1-phosphate. Cardiovasc Res 2009; 82(2): 313-323.
24. Somers SJ, Frias M, Lacerda L, Opie LH, Lecour S. Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection. Cardiovasc Drugs Ther 2012; 26(3): 1-11.
25. Smith RM, Suleman N, McCarthy J, Sack MN. Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNFalpha gene. Cardiovasc Res 2002; 55(3): 553-560. (Pubitemid 34874950)
26. Lecour S, Rochette L, Opie L. Free radicals trigger TNF alpha-induced cardioprotection. Cardiovasc Res 2005; 65(1): 239-243. (Pubitemid 40038497)
27. Williams SD, Ford DA. 2001. Calcium-independent phospholipase A2 mediates CREB phosphorylation and c-fos expression during ischemia. Am J Physiol Heart Circ Physiol 2001; 281(1): H168-H176.
28. Lewin TM, de Jong H, Schwerbrock NJ, Hammond LE, Watkins S M, Combs TP, et al. Mice deficient in mitochondrial glycerol-3-phosphate acyltransferase-1 have diminished myocardial triacylglycerol accumulation during lipogenic diet and altered phospholipid fatty acid composition. Biochim Biophys Acta (BBA) Molec Cell Biol Lipids 2008; 1781(6): 352-358.
29. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 2009; 82(2): 201-211.
30. Vessey DA, Li L, Kelley M, Zhang J, Karliner JS. Sphingosine can pre- and post-condition heart and utilizes a different mechanism from sphingosine 1-phosphate. J Biochem Mol Toxicol 2008; 22(2): 113-118. (Pubitemid 351657194)
31. Keul P, Sattler K, Levkau B. HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Fail Rev 2007; 12(3-4): 301-306. (Pubitemid 350176703)
32. Wang M, Zhang W, Crisostomo P, Markel T, Meldrum KK, Fu XY et al. Sex differences in endothelial STAT3 mediate sex differences in myocardial inflammation. Am J Physiol Endocrinol Metab 2007; 293(3): E872-E877. (Pubitemid 47359002)
33. Barry SP, Townsend PA, Knight RA, Scarabelli TM, Latchman DS, Stephanou A. STAT3 modulates the DNA damage response pathway. Int J Exp Pathol 2010; 91(6): 506-514.
34. Pedretti S, Raddatz E. STAT3α interacts with nuclear GSK3beta and cytoplasmic RISK pathway and stabilizes rhythm in the anoxic-reoxygenated embryonic heart. Basic Res Cardiol 2011; 106(3): 355-369.35.
35. Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R. Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 2010; 105(6): 771-785.
36. Heusch G, Musiolik J, Gedik N, Skyschally A. Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion novelty and significance. Circ Res 2011; 109(11): 1302-1308.
37. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007; 59: 418-458.